Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

At the time, the BCR-ABL tyrosine kinase was the best-credentialed tyrosine kinase target in oncology. A couple of years earlier, I had advised Nick that CML, driven by BCR-ABL kinase activity ...

ELVN-001 targets the BCR-ABL gene fusion, addressing resistance ... mutation and confers resistance to all generations of tyrosine kinase inhibitors. A number of molecules, some of which have ...

As the disease progresses, it’s important to regularly adapt treatment strategies based on consistent monitoring of BCR-ABL levels ... My Current Treatment? Tyrosine kinase inhibitors (TKIs ...